Inactive Instrument

Audentes Therapeutics, Inc.

Equities

US05070R1041

Biotechnology & Medical Research

Audentes Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019

November 07, 2019 at 10:24 pm

Audentes Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating loss was USD 47.825 million compared to USD 37.735 million a year ago. Net loss was USD 45.741 million compared to USD 36.291 million a year ago. Basic loss per share was USD 1 compared to USD 0.97 a year ago. For the nine months, operating loss was USD 146.732 million compared to USD 96.774 million a year ago. Net loss was USD 139.896 million compared to USD 93.229 million a year ago. Basic loss per share was USD 3.14 compared to USD 2.57 a year ago.

Latest news about Audentes Therapeutics, Inc.

Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	03-14	CI
Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	07/11/22	CI
Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	20/10/22	CI
Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy	24/12/20	CI
Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy	21/08/20	CI
Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources	21/04/20	CI
Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina	18/02/20	CI
Audentes Therapeutics, Inc. Announces Management Changes	15/01/20	CI
Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31	15/01/20	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index	15/01/20	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index	15/01/20	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index	15/01/20	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index	14/01/20	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Biotechnology Index	14/01/20	CI
Astellas US Holding, Inc. completed the acquisition of Audentes Therapeutics, Inc..	13/01/20	CI
Takeda Pharmaceutical : Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million	27/12/19	RE
Roche : dives deeper into gene therapy with $1.15 billion Sarepta licensing deal	23/12/19	RE
Japanese shares slip on concerns of longer trade war	04/12/19	RE
Wall Street falls as trade hopes wane	03/12/19	RE
Astellas Pharma : Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet	03/12/19	RE
Nikkei slips on fresh global trade concerns, weak U.S. data	03/12/19	RE
Astellas US Holding, Inc. entered into a definitive agreement to acquire Audentes Therapeutics, Inc. for $2.8 billion.	01/12/19	CI
Audentes Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	07/11/19	CI
Transcript : Audentes Therapeutics, Inc., Q3 2019 Earnings Call, Nov 07, 2019	07/11/19
Audentes Therapeutics Announces New Positive Data from ASPIRO	09/10/19	CI

Chart Audentes Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+17.54%	123B
REGENERON PHARMACEUTICALS, INC.	+16.91%	111B
BIONTECH SE	-9.28%	23.63B
ARGENX SE	+4.40%	22.58B
WUXI APPTEC CO., LTD.	-38.15%	17.61B
BEIGENE, LTD.	-7.86%	17.6B
GENMAB A/S	-15.36%	17.26B
NEUROCRINE BIOSCIENCES, INC.	+3.26%	13.55B
SAREPTA THERAPEUTICS, INC.	+29.30%	11.34B

Bio Therapeutic Drugs